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Background/aim: The aim of this study was to compare the effects of single and repeated trimetazidine (TMZ) administration against
warm hepatic ischemia/reperfusion (I/R) injury and to explore the possible mechanisms affected by TMZ.
Materials and methods: Wistar rats were divided into 4 groups (n = 6). Sham: rats were subjected to dissection. I/R: rats were subjected
to 60 min of partial hepatic ischemia followed by 24 h of reperfusion. TMZ1: Same as I/R group but rats were pretreated with a single
dose of TMZ (10 mg/kg, intraperitoneal injection) 30 min before warm ischemia. TMZ3: Same as I/R but rats were treated with 10 mg/
kg TMZ for 3 successive days.
Results: TMZ treatment decreased liver injury, lipid peroxidation, and apoptosis. The repeated administration of TMZ conferred
more protection than the single dose treatment concerning all studied parameters. In parallel, we noted a significant increase in
phosphorylated adenosine monophosphate activated protein kinase (p-AMPK) and endothelial nitric oxide synthase (eNOS) levels in
TMZ3 as compared to TMZ1.
Conclusion: Repeated administration of TMZ for 3 days was more efficient than a single dose of TMZ in protecting the liver against I/R
induced apoptosis and lipid peroxidation. These effects implicate AMPK and eNOS activation.
Key words: Ischemia/reperfusion injury, liver, trimetazidine, adenosine monophosphate activated protein kinase, endothelial nitric
oxide synthase, apoptosis

1. Introduction
Hepatic ischemia/reperfusion (I/R) injury is a pivotal
clinical problem occurring in many conditions such
as liver transplantation, major hepatectomy, trauma,
and hemorrhagic shock (1). The prevention of liver
vulnerability against I/R damage is a determinant in
preserving hepatic function and accelerating the organ’s
recovery (2). Pharmacological preconditioning has been
widely explored as an effective strategy to overcome the
pathophysiological changes caused by hepatic warm I/R
injury (3). Trimetazidine (1-2(2,3,4- trimethoxibenzyl)piperazine) (TMZ), an antiischemic drug, decreases
fatty acid oxidation and stimulates glucose utilization
leading to the production of adenosine triphosphate
(ATP) with less oxygen consumption (1,3). In addition,
experimental and clinical results have shown that TMZ
* Correspondence: mahfoudhasma@yahoo.fr
** These authors contributed equally to this work.
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has a number of potentially useful cytoprotective impacts.
It has been reported that it limits intracellular acidosis,
reduces sodium and calcium accumulation into cells (4),
and decreases cytolysis and membrane injury caused by
oxygen free radicals (5,6). In addition, TMZ conserves
mitochondrial function and energy metabolism (7).
Several routes, times, and doses of administration of
this antioxidant agent have been proposed in the literature
(5,8,9). Tsimoyiannis et al. (10) demonstrated that a single
dose of TMZ (2.5 mg/kg) given before or after the ischemic
episode gave significant protection to hepatocytes, but
pretreatment twice for 5 days was more effective. Settaf
et al. (11) demonstrated that TMZ, administered at 80
mg per day during 5 days before the procedure until the
day of surgery, reduced postoperative transaminase levels
when compared to the placebo group. Furthermore, the
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hospital stay was significantly shorter in the TMZ treated
group. Regarding the encouraging results found, further
trials evaluating the optimal dose response relationship are
required. The objective of our study was to compare the
effects of single dose and repeated TMZ administration
against warm hepatic I/R injury and to explore the possible
mechanisms implicated in these effects.
2. Materials and methods
2.1. Experimental design
Male Wistar rats weighing 200–250 g were used in this
study. All procedures were carried out in accordance with
the European Union Regulations (Directive 86/609/CEE)
for animal experiments. All animals were housed under
standard conditions with a 12 h light/dark routine and free
access to water and food. They were anesthetized with an
intraperitoneal (ip) injection of pentobarbital (5%).
A model of segmental (70%) warm hepatic I/R was used
(1). Briefly, after a midline laparotomy, a nontraumatic
vascular clamp was used to interrupt the arterial and
portal venous blood supply to the left and median liver
lobes for 60 min. Reperfusion was initiated by removal of
the clamp. During the surgery, animals were placed onto a
thermostatically controlled warm board to maintain body
temperature at 37 °C. The rats were sacrificed after 24 h of
reperfusion, and liver and serum samples were collected
for analyses.
2.2. Experimental groups
Animals were randomly assigned into the following
experimental groups, each containing 6 rats. In the
sham group, the rats were subjected to laparotomy and
hepatic triad vessels were only dissected. In the I/R group,
rats were subjected to 60 min of partial (70%) ischemia
followed by 24 h of reperfusion (12). The rats of the TMZ1
group were treated with 10 mg/kg (ip injection) of TMZ
(Sigma Chemical, St. Louis, MO, USA) 30 min before
warm ischemia (13) with the TMZ dissolved in NaCl 9‰.
Finally, the rats of the TMZ3 group were treated with 10
mg/kg (ip injection) of TMZ for 3 successive days. On the
third day, TMZ was injected 30 min before warm ischemia.
2.3. Biochemical assays
2.3.1 Liver injury
Aspartate
aminotransferase
(AST),
alanine
aminotransferase (ALT), alkaline phosphatase (ALP), and
gamma glutamyltransferase (GGT) activities in serum
were measured by commercial DiaSys kits (Diagnostic
System, Germany) following supplier instructions.
2.3.2. Lipid peroxidation assessment
Malondialdehyde (MDA) is an end product of
peroxidation of cell membrane lipids caused by oxygen
derived free radicals. It was measured in liver tissue using
the thiobarbiturate reaction at 530 nm (14).

2.3.3 Western blots analysis
Liver tissue was homogenized in Hepes buffer (40 mM
NaCl, 1 mM EDTA, Triton-X 0.1%, glycerol 5%, NaP2O7
10 mM, β-glycerophosphate 10 mM, Na3VO4 1.5 mM,
NaF 50 mM, 1 complete tablet/100 mL, Hepes-KOH
pH = 7.4 50 mM) using a Teflon homogenizer. Then
the homogenates were centrifuged at 15,000 rpm for 20
min at 4 °C. Protein concentrations were determined
according to the Bradford method. Protein extracts (50
µg/lane) were then separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred to
polyvinyldene fluoride (PVDF) membranes. Membranes
were immunoblotted overnight at 4 °C with antibodies
directed against total and phosphorylated AMPK,
cytochrome C, cleaved caspase 9, cleaved caspase 3 (Cell
Signaling Technology Inc., Beverly, MA, USA), eNOS,
and β actin (Sigma Chemical, St. Louis, MO, USA). The
bands were detected using chemiluminescent kit (Bio-Rad
Laboratories, Hercules, CA, USA) and quantified using
the Quantity One software for image analysis. Results were
expressed as densitometric ratios between the protein of
interest and the loading control.
2.3.4. Statistical analysis
The data are presented as means ± standard error of the
mean (SEM). Statistical analysis was performed using
one-way analysis of variance, followed by Newman–Keuls
multiple comparisons. P < 0.05 was considered statistically
significant.
3. Results
3.1. Effect of TMZ treatment on liver injury
Liver damage was assessed by transaminases (ALT and
AST) activities. As revealed by Figures 1a and 1b, hepatic
I/R resulted in a significant (P < 0.05) increase in plasma
ALT and AST activities when compared to the sham
operated group. The use of TMZ treatments significantly
(P < 0.05) decreased cell injury compare with the I/R
group. Interestingly, the largest reduction in ALT and AST
levels was observed in the TMZ3 group as compared to
TMZ1 group. The difference was statistically significant (P
< 0.05) between both groups.
In parallel, we examined the impact of TMZ
administration on ALP activity. As revealed by Figure 1c,
hepatic I/R induced a significant (P < 0.05) increase in ALP
activity in the sham group. TMZ pretreatment resulted in
a significant (P < 0.05) reduction in this parameter when
compared to the I/R group. Interestingly, the lowest activity
of ALP was observed in the TMZ3 group when compared
to the TMZ1 group. The difference was statistically
significant (P < 0.05) between both groups.
Similarly, upon I/R injury, serum GGT activity was
significantly increased in the I/R group as compared to the
sham group (Figure 1d). This rise was then significantly (P
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Figure 1. Evaluation of alanine amino transaminase (ALT) (a), aspartate amino transaminase (AST) (b), alkaline phosphatase (ALP)
(c), and gamma glutamyltransferase (GGT) (d) activities. Results are presented as mean ± standard error of the mean (n = 6 in each
group). * P < 0.05 vs. sham group. # P < 0.05 vs. I/R group. ‡ P < 0.05 vs. TMZ1 group.
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< 0.05) attenuated by TMZ pretreatments when compared
to the I/R group. A significant difference was detected
among both TMZ groups.
3.2. Effect of TMZ treatment on lipid peroxidation
We examined the protective effect of TMZ on lipid
peroxidation (Figure 2). Hepatic I/R caused a significant
(P < 0.05) rise in tissue MDA level compared with the
sham group. After the TMZ treatment, we observed a
significant drop in this parameter compared to the I/R
group. However, no statistical difference was obtained
between TMZ groups.
3.3. Effect of TMZ treatment on apoptotic proteins levels
We also determined whether TMZ was able to reduce
apoptosis of liver cells. The relevance of apoptosis was
assessed by tissue cytochrome C, cleaved caspases 9, and
cleaved caspases 3 proteins levels (Figure 3). A unique
administration of TMZ decreased the cleaved caspase 3
and cleaved caspase 9 protein levels (P < 0.05 versus I/R,
respectively) but no significant difference was observed
concerning cytochrome C when compared to the I/R
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Figure 2. Evaluation of malondialdehyde concentration in tissue.
Results are presented as mean ± standard error of the mean (n=6
in each group). * P < 0.05 vs. sham group. # P < 0.05 vs. I/R group.
‡ P < 0.05 vs. TMZ1 group.

group. However, when TMZ was administered for 3 days,
we noted an important decrease in the amount of all
studied parameters regarding I/R. In addition, there was
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Figure 3. Western blot of cytochrome C (a), cleaved caspase 9 (b), and cleaved caspase 3 (c) levels. One representative blot of 6
independent experiments is shown at the top whereas densitometric analysis is shown at the bottom. Results are presented as mean ±
standard error of the mean (n = 6 in each group). * P < 0.05 vs. sham group. # P <0.05 vs. I/R group. ‡ P < 0.05 vs. TMZ1 group.

a significant difference between TMZ groups regarding
cytochrome C and cleaved caspase 9 (P < 0.05, respectively)
except for cleaved caspase 3 (P > 0.05).
3.4. Effects of TMZ treatment on the p-AMPK and eNOS
levels
As indicated in Figure 4, hepatic warm I/R decreased
p-AMPK protein level (P < 0.05) when compared to sham
tissue, but TMZ administration augmented the p-AMPK
level. This increase was statistically significant compared
to the I/R group (P < 0.05). The AMPK phosphorylation
was furthermore enhanced by the repetitive TMZ
administration when compared to the TMZ1 group. The
difference between the 2 groups was statistically significant
(P < 0.05).
In parallel, Western blot analysis denoted that the
immediate administration of TMZ before warm hepatic
I/R did not affect the amount of eNOS compared to the I/R
group. However, the repetitive administration of TMZ for
3 days induced an important rise in the eNOS level. The
difference was statistically significant (P < 0.05) between
the I/R and TMZ1 groups.

4. Discussion
The objective of our study was to investigate the protective
effect of TMZ preconditioning in hepatic I/R injury using 2
dosing protocols and its effects in the signaling mechanism
involved in the physiopathology of liver ischemia.
Our results consolidate previous reports demonstrating
that TMZ protects rat liver against I/R injury (13). Rats
pretreated with TMZ showed reduced activity of AST,
PAL, and GGT. We noted that repeated administration
of TMZ for 3 days was more efficient in reducing liver
damage than a single dose. A growing body of evidence
has proven that TMZ has antioxidant effects and its role
on lipid peroxidation inhibition has been well established
in different organs (8,9). Lipid peroxidation disrupts
membrane fluidity and cell compartmentalization, which
results in cell lysis (3). The antiischemic effect of TMZ is
usually attributed to its impact on the balance between
fatty acid and glucose oxidation. TMZ favors a shift from
fatty acid oxidation to glucose oxidation, via the inhibition
of the mitochondrial long-chain 3-ketoacyl CoA thiolase,
and thereby attenuates the detrimental effects of I/R (8).
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Figure 4. Western blot of total and phosphorylated-AMPK (a), and eNOS (b) levels. One representative blot of 6 independent
experiments is shown at the top whereas densitometric analysis is shown at the bottom. Results are presented as mean ± standard
error of the mean (n = 6 in each group). * P < 0.05 vs. sham group. # P < 0.05 vs. I/R group. ‡ P < 0.05 vs. TMZ1 group.

Elimadi et al. (14) reported that TMZ produced some
metabolites that might possess antioxidant capacity
when it is metabolized by the liver, the major site of drug
metabolism.
In line with this, our current results revealed that the
pretreatment of rats with TMZ before the induction of liver
ischemia decreased the leakage of hepatocyte enzymes
and prevented lipid peroxidation. We noted that repeated
administration of TMZ for 3 days was more efficient in
reducing liver damage than a single dose. However, no
significant change was noted between the 2 models of
TMZ administration concerning MDA concentration in
tissues.
We further showed that TMZ reduced apoptosis.
Indeed, Western blot results revealed that TMZ
pretreatment significantly reduced the cleaved caspase 9,
the cleaved caspase 3 levels, and cytochrome C release when
compared to the I/R group. Previous studies demonstrated
that TMZ could limit apoptotic death in different
experimental models (15,16). These apoptotic proteins
are known to have a pivotal role in I/R pathophysiology
(15). In fact, TMZ might bind to the inner mitochondrial
membrane and inhibit the activation of the permeability
transition pore and subsequent cytochrome C release (17).
When released, cytochrome C forms a complex with Apaf
1 and procaspase 9, resulting in the activation of caspase
9, which induces caspase 3 activation and apoptosis. Data
from the present study provide strong evidence that TMZ
preconditioning preserves mitochondrial integrity and
reduces mitochondria mediated apoptosis. It seems that
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the administration of TMZ for 3 days was more effective
in reducing apoptosis.
The hepatoprotective mechanisms of TMZ are complex
(9,16). Khan et al. (9) reported that TMZ is cardioprotective
when administered before reperfusion and that this
protection appears to be mediated by activation of p38
mitogen-activated protein kinase and Akt signaling
pathway. Moreover, Wu et al. (18) demonstrated that TMZ
induced the activation of Akt/eNOS signaling pathways
to mitigate H2O2 induced oxidative stress and cell death.
To gain further insight into the mechanisms involved
in the hepatoprotective effect of TMZ and the influence
of the protocol of administration, we investigated the
activation of AMPK and eNOS signaling pathways, which
play a critical role in protecting various organs against I/R
injury including the heart (19) and kidney (20). It also
has a protective role against hepatic I/R injury in the liver
(21). Bouma et al. (22) demonstrated that the addition of
5-amino 4 imidazole carboxamide riboside, an AMPK
activator, to University of Wisconsin solution improved
liver graft preservation. AMPK promotes ATP generating
pathways, while inhibiting energy consuming anabolic ones
(23). AMPK also appears to function as a sensor for other
signaling pathways. A relationship between AMPK and
nitric oxide (NO) has previously been described. Zaouali
et al. (24) demonstrated that increased levels of eNOS and
NO generation are in part due to AMPK phosphorylation
after cold I/R injury in rat liver. It is well established
that NO plays a crucial role in defending organs against
I/R injury through its antioxidant, antiinflammatory,
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and antiapoptotic capacities (25). Moreover, Jayle et al.
have demonstrated that the TMZ protective effect was
associated with NO generation in a pig kidney model of
I/R (6). Our results revealed that repeated TMZ treatment
enhanced AMPK phosphorylation and eNOS activation.
However, single dose administration activated AMPK but
not eNOS.
Taken together, all these data suggested that the
pretreatment of rats with TMZ before the induction of
liver I/R decreased liver injury and oxidative stress. The
underlying protective mechanism was the activation of
AMPK/eNOS cell signaling pathway and the inhibition
of apoptosis. Furthermore, we demonstrated that dosing
time of TMZ determines the mechanisms and the degree
of protection. Elimadi et al. (14) investigated the effect of
an intramuscular injection of different doses of TMZ on
hepatic warm I/R injury. They demonstrated that 10 mg/
kg per day for 7 days was the optimal TMZ dosage that
gave the maximal protective effects at both cellular and

mitochondrial level. However, Cau et al. (17) demonstrated
that intravenous administration of TMZ is protective
against renal I/R injury at a dose of 5 and 10 mg/kg in
an in vivo pig model of warm I/R and that the dose of 10
mg/kg did not increase TMZ efficiency. The discrepancies
observed between results may implicate, at least partially,
the routes, timing, and doses of TMZ administration, as
well as I/R protocols. Further investigations to evaluate
the optimal time and dose of administration of TMZ are
required to have more insight into clinical translation.
In light of these findings, we suggest that repeated
administration of TMZ for 3 days was more efficient than
a single dose of TMZ in protecting the liver against I/R
induced apoptosis and lipid peroxidation. These protective
effects implicate AMPK and eNOS activation.
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